Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2024
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, this report focuses on corporate governance updates rather than financial performance data.
Material Changes
- Executive Appointment: The company appointed Abby Macnish Niven as Chief Financial Officer.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves primarily to incorporate the appointment of the new CFO into existing Registration Statements (Form S-8 and Form F-3).
Investor Verification Checklist
- Verify the background and qualifications of the newly appointed CFO, Abby Macnish Niven.
- Review the referenced Registration Statements (S-8 and F-3) for details on how this appointment impacts ongoing capital raising or equity plans.
- Confirm the company's current cash runway and funding status, as this Form 6-K does not disclose financial metrics.